Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Hypertrophic Scars Therapeutics: Global Pipeline Analysis 2017 - Clinical Trials & Results, Patent, Designations, and Collaborations -

Research and Markets
Posted on: 07 Mar 18

The "Hypertrophic Scars Therapeutics Pipeline Analysis, 2017 - Clinical Trials & Results, Patent, Designations, Collaborations, and Other Developments" report has been added to's offering.

Hypertrophic scars currently exhibits a growing pipeline with nine drug candidates.

Body cells known as myofibroblasts produce excessive collagen during healing process which can be deposited as a bump and later changes to a hypertrophic scar. The study analyzed that the hypertrophic scars therapeutics pipeline comprises approximately nine drug candidates in different stages of development.

Majority of the pipeline drug candidates are being developed to be administered by the topical route. SCX-001 cream has demonstrated anti-scarring effects in two in-vivo Pre-clinical dermal models. SCX-001 cream's safety as a topical agent has also been confirmed in non-clinical Investigational New Drug (IND) in-vitro and in-vivo studies.

The drug development process involves specific targets such as connective tissue growth factor inhibition which is the probable mechanism of action for the treatment of hypertrophic scars. Thus, this specific targeted therapy provides opportunities to the companies for better and targeted drug development.

Technological advancements have been strengthening the development of pipeline drugs for the treatment of hypertrophic scars. For instance, The RNA interference (RNAi) technology, was used in the development of OLX101 by OliX Pharmaceuticals, Inc.

Some of the players developing drugs for the treatment of hypertrophic scars include RXi Pharmaceuticals Corporation, Sirnaomics, Inc., ScarX Therapeutics, Inc., and Scarless Laboratories, Inc.

Report Segmentation

  • By Phase
  • By Molecule Type
  • By Route of Administration
  • By Company

Key Topics Covered

Chapter 1. Research Background

Chapter 2. Research Methodology

Chapter 3. Executive Summary

Chapter 4. Pipeline Outlook

Chapter 5. Hypertrophic Scars Therapeutics Pipeline Analysis by Phase (2017)

Chapter 6. Clinical Trials Analysis

Chapter 7. Competitive Landscape

Chapter 8. Company Profiles

For more information about this report visit

View source version on

Business Wire

Last updated on: 07/03/2018

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.